Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

16.28
-0.1600-0.97%
Volume:507.11K
Turnover:8.26M
Market Cap:995.31M
PE:-9.91
High:16.61
Open:16.43
Low:16.18
Close:16.44
52wk High:35.34
52wk Low:12.12
Shares:61.14M
Float Shares:42.53M
Volume Ratio:0.75
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6429
EPS(LYR):-1.8336
ROE:-10.70%
ROA:-8.80%
PB:1.07
PE(LYR):-8.88

Loading ...

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA)

TIPRANKS
·
Apr 29

Janux Therapeutics Adjusts Board Class Structure for Director

TIPRANKS
·
Apr 29

Janux reclassifies Eric Dobmeier as Class II director, keeps him on compensation committee

Reuters
·
Apr 29

Janux Therapeutics announces annual shareholder meeting notice

Reuters
·
Apr 29

Janux Therapeutics Is Maintained at Buy by Jones Trading

Dow Jones
·
Apr 29

Janux Therapeutics price target lowered to $28 from $50 at JonesResearch

TIPRANKS
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Qiagen (QGEN), Eli Lilly & Co (LLY) and Janux Therapeutics Inc (JANX)

TIPRANKS
·
Apr 28

Janux Therapeutics announces discontinuation of JANX008 clinical development

TIPRANKS
·
Apr 28

Janux Therapeutics discontinues JANX008 clinical development after Phase 1a review

Reuters
·
Apr 28

Janux Therapeutics Announces Discontinuation of Janx008 Clinical Development

THOMSON REUTERS
·
Apr 28

Janux’s JANX011 First‑in‑Human Study: Early Safety Readout Could Shape Autoimmune Upside

TIPRANKS
·
Apr 24

Barclays Downgrades Janux Therapeutics to Underweight From Overweight, Adjusts Price Target to $14 From $29

MT Newswires Live
·
Apr 20

Janux Therapeutics Shares Down 3.3% Premarket After Barclays Cuts to Underweight From Overweight

THOMSON REUTERS
·
Apr 20

BRIEF-Janux Therapeutics Announces First Participant Dosed In Phase 1 Study Of Janx014

Reuters
·
Apr 17

Janux Therapeutics says first patient dosed in Phase 1 study of JANX014

TIPRANKS
·
Apr 17

Janux doses first patient in Phase 1 trial of JANX014 for prostate cancer

Reuters
·
Apr 17

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of Janx014

THOMSON REUTERS
·
Apr 17

Janux Therapeutics Lacking Near-Term Catalysts, UBS Says

MT Newswires Live
·
Apr 16

Janux Therapeutics Inc : UBS Cuts Target Price to $15 From $57

THOMSON REUTERS
·
Apr 15

UBS Downgrades Janux Therapeutics to Neutral From Buy, Adjusts PT to $15 From $57

MT Newswires Live
·
Apr 15